Latest Janssen Pharmaceutical Companies Stories
Presentations include late-breaking final results from the Phase 3 OPTIMIST trials and interim results from the Phase 2 IMPACT trial of simeprevir CORK, Ireland, April 8, 2015 /PRNewswire/
New Focus in Disease Prevention, Disease Interception, and the Microbiome to Propel Scientific Innovation RARITAN, N.J., Feb.
Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety WASHINGTON, Jan.
- An armed gangster.